Bristol Myers Squibb (CELG-RI) Change in Inventory (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Change in Inventory of $36.0 million for Q2 2026, up 1000.0% year-over-year from $3.3 million in Q2 2025, and up 357.14% quarter-over-quarter from -$14.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Change in Inventory (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Change in Inventory for 18 consecutive years, with $36.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Inventory rose 1000.0% year-over-year to $36.0 million; the TTM figure through Jun 2026 stood at $41.0 million (down 80.29% YoY), while the FY2025 annual figure was $184.0 million, down 62.14% from the prior year.
- Change in Inventory improved to $36.0 million in Q2 2026 per CELG-RI's latest filing, from -$14.0 million in the prior quarter.
- Across five years, Change in Inventory topped out at $282.0 million in Q1 2023 and bottomed at -$175.0 million in Q4 2024.
- Historically, Change in Inventory has averaged $84.0 million across 5 years, with a median of $38.5 million in 2022.
- Annual changes were most pronounced in 2023 — Change in Inventory jumped 28300.0% — and 2024, when it sank 188.83%.
- Bristol Myers Squibb's Change in Inventory stood at $41.0 million in 2022, then soared by 380.49% to $197.0 million in 2023, then sank by 188.83% to -$175.0 million in 2024, then surged by 59.43% to -$71.0 million in 2025, then surged by 150.7% to $36.0 million in 2026.
- Business Quant data shows CELG-RI's Change in Inventory at $36.0 million in Q2 2026, -$14.0 million in Q1 2026, and -$71.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 571.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 143.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 31.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 145.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 36.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.00 Mn |
| Jun 30, 2026 | 36.00 Mn |
| Mar 31, 2026 | -14.00 Mn |
| Mar 31, 2026 | -14.00 Mn |
| Dec 31, 2025 | -71.00 Mn |
| Dec 31, 2025 | -71.00 Mn |
| Sep 30, 2025 | 90.00 Mn |
| Sep 30, 2025 | 90.00 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Jun 30, 2025 | -4.00 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | -175.00 Mn |
| Dec 31, 2024 | -175.00 Mn |
| Sep 30, 2024 | 218.00 Mn |
| Sep 30, 2024 | 218.00 Mn |
| Jun 30, 2024 | 225.00 Mn |
| Jun 30, 2024 | 225.00 Mn |
| Mar 31, 2024 | 218.00 Mn |
| Mar 31, 2024 | 218.00 Mn |